Your shopping cart is currently empty

LH1753 is an orally active inhibitor of L-cystine crystallization, with an EC50 of 29.5 nM. It is applicable in research related to Cystinuria.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 2-4 weeks | 2-4 weeks | |
| 50 mg | $1,980 | 2-4 weeks | 2-4 weeks | |
| 100 mg | $2,500 | 2-4 weeks | 2-4 weeks |
| Description | LH1753 is an orally active inhibitor of L-cystine crystallization, with an EC50 of 29.5 nM. It is applicable in research related to Cystinuria. |
| In vivo | LH1753 (150 μmol/kg, administered orally, once daily for eight weeks) inhibits the formation of L-cystine stones but does not affect the growth of the cystinuria mouse model with Slc3a1 gene knockout [1]. |
| Molecular Weight | 630.57 |
| Formula | C22H44Cl4N6O2S2 |
| Cas No. | 2650492-10-5 |
| Smiles | O=C(N1CCC2(CCCN2)CC1)[C@@H](N)CSSC[C@H](N)C(N3CCC4(CCCN4)CC3)=O.Cl.Cl.Cl.Cl |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.